Trial Profile
A 5-Year Prospective Observational Registry to Assess Adverse Events of Interest and Effectiveness in Adults With Active, Autoantibody-Positive Systemic Lupus Erythematosus Treated With or Without BENLYSTA (Belimumab)
Status:
Active, no longer recruiting
Phase of Trial:
Phase IV
Latest Information Update: 27 Jan 2023
Price :
$35
*
At a glance
- Drugs Belimumab (Primary) ; Antimalarials; Corticosteroids; Immunosuppressants
- Indications Systemic lupus erythematosus
- Focus Adverse reactions
- Acronyms SABLE
- Sponsors GSK; Human Genome Sciences
- 02 Jun 2021 Planned End Date changed from 16 Jan 2025 to 17 Feb 2025.
- 02 Jun 2021 Planned primary completion date changed from 16 Jan 2025 to 17 Feb 2025.
- 28 Feb 2020 Status changed from recruiting to active, no longer recruiting.